Qiming U.S. Healthcare Fund II, L.P. - 02 Aug 2021 Form 4 Insider Report for Icosavax, Inc.

Reporting relationship: Former 10% Owner
Issuer ticker: N/A
Reported as of: 02 Aug 2021
Net transaction value: +$3,320,265
SEC form: 4
Accepted by SEC: 02 Aug 2021, 21:27:12 UTC
Prior SEC filing: 28 Jul 2021
Next SEC filing: 01 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Qiming U.S. Healthcare Fund II, L.P., by Qiming U.S. Healthcare GP II, LLC, its General Partner

Key filing fact

Qiming U.S. Healthcare Fund II, L.P. filed Form 4 for Icosavax, Inc. on 02 Aug 2021.

Key facts

This page summarizes Qiming U.S. Healthcare Fund II, L.P.'s Form 4 filing for Icosavax, Inc..
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Aug 2021, 21:27.

Change

Previous filing in this sequence was filed on 28 Jul 2021.
Current net transaction value: +$3,320,265.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICVX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +3,310,228
Change %
Price: $0.000000
Shares after: 3,310,228
Date: 02 Aug 2021
Ownership: Direct
Footnotes: F1, F2

ICVX transaction

Common Stock

Purchase

Transaction value: $3,000,000
Shares: +200,000
Change %: +6%
Price: $15.00
Shares after: 3,510,228
Date: 02 Aug 2021
Ownership: Direct
Footnotes: F2, F5

ICVX transaction

Common Stock

Purchase

Transaction value: $120,270
Shares: +8,018
Change %: +0.23%
Price: $15.00
Shares after: 3,518,246
Date: 02 Aug 2021
Ownership: Direct
Footnotes: F3

ICVX transaction

Common Stock

Purchase

Transaction value: $199,995
Shares: +13,333
Change %: +0.38%
Price: $15.00
Shares after: 3,523,561
Date: 02 Aug 2021
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICVX transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -12,480,498
Change %: -100%
Price
Shares after: 0
Date: 02 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,003,224
Exercise price: $0.000000
Footnotes: F1, F2

ICVX transaction Derivative

Series B-1 Preferred Stock

Conversion of derivative security

Transaction value
Shares: -1,275,817
Change %: -100%
Price
Shares after: 0
Date: 02 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 307,004
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Qiming U.S. Healthcare Fund II, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

On August 2, 2021, the shares of Series A-1 Preferred Stock and Series B-1 Preferred Stock converted into shares of the Issuer's common stock at a ratio of 4.1557-for-1 automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, Qiming U.S. Healthcare Fund II, L.P. ("Qiming") is no longer a 10% owner of the Issuer and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer.

Footnote F2

The securities are directly held by Qiming. Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming. Gary Rieschel and Mark McDade are the managing members of Qiming GP. As a result, each of Qiming GP and Messrs. Rieschel and McDade may be deemed to beneficially own the shares held by Qiming.

Footnote F3

Shares reported herein as purchased on August 2, 2021 represent 8,018 shares of Common Stock purchased by Mark McDade.

Footnote F4

Shares reported herein as purchased on August 2, 2021 represent 13,333 shares of Common Stock purchased by Gary Rieschel.

Footnote F5

Shares reported herein as purchased on August 2, 2021 represent 200,000 shares of Common Stock purchased by Qiming.